Drug Profile
Research programme: asthma therapy - Oscient/Schering-Plough
Alternative Names: Asthma therapy research programme - Oscient/Schering-PloughLatest Information Update: 25 Oct 2007
Price :
$50
*
At a glance
- Originator Oscient Pharmaceuticals; Schering-Plough
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 25 Oct 2006 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 17 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals